[Opinion] Should the 90% CI for GMR be required to encompass 1 [RSABE / ABEL]

posted by bebac_fan – US, 2018-03-28 21:23 (2013 d 23:55 ago) – Posting: # 18603
Views: 9,591

Dear ElMaestro,

Thank you for your input. I agree that this rule would punish sponsors have high sample sizes.

I understand this is also a potential mechanism of abuse to get poor drugs approved: Sponsors may increase sample sizes arbitrarily to meet BE. Would my proposed approach prevent that?

Lets take a drug that comes in 100, 112, and 125. Theoretically, a sponsor could get 100, 112, AND 125 dosage forms (assuming CMC doesn't catch it) approved for 112 if they use sample sizes big enough :-) This is my biggest concern.

Thanks again for your input -
bebac_fan


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
22,764 posts in 4,776 threads, 1,628 registered users;
16 visitors (1 registered, 15 guests [including 2 identified bots]).
Forum time: 21:19 CEST (Europe/Vienna)

The object of statistics is information.
The objective of statistics is the understanding of information
contained in data.    Irwin and Marylees Miller

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5